Conditions: ADHD
Keywords: Attention Deficit Hyperactivity Disorder ADHD fMRI Imaging Vyvanse Stimulant Medication Treatment Clinical Trial Adult
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 30
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the effects of Vyvanse, an FDA approved medication used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), on brain activity in adults with attention-deficit hyperactivity disorder (ADHD). Participants may qualify for participation in this study because they have ADHD and are willing to participate in two Functional Magnetic Resonance Imaging (fMRI) scans and receive Vyvanse for treatment of their symptoms. Another purpose of this study is to collect and bank samples of blood for research to examine how genes influence brain activation seen during the brain scans. The study also seeks to find out whether certain genes are related to ADHD. Participants' entire genetic makeup will not be determined from this sample.

Detailed description:

Arms:
arm 1: Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg arm 2: Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg

Interventions: intervention 1: Lisdexamfetamine
Intervention descriptions: intervention 1: Escalating stepped dose titration: 30, 50 or 70mg

Protocol document: